1. Home
  2. MFA vs ABUS Comparison

MFA vs ABUS Comparison

Compare MFA & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFA Financial Inc.

MFA

MFA Financial Inc.

HOLD

Current Price

$8.78

Market Cap

957.0M

Sector

Real Estate

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$5.13

Market Cap

839.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MFA
ABUS
Founded
1997
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
957.0M
839.5M
IPO Year
1998
2008

Fundamental Metrics

Financial Performance
Metric
MFA
ABUS
Price
$8.78
$5.13
Analyst Decision
Buy
Strong Buy
Analyst Count
6
1
Target Price
$11.05
$5.00
AVG Volume (30 Days)
1.4M
3.9M
Earning Date
05-05-2026
05-14-2026
Dividend Yield
14.16%
N/A
EPS Growth
58.54
55.26
EPS
0.23
0.84
Revenue
N/A
$14,083,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$10.02
$239.71
P/E Ratio
$37.74
$6.06
Revenue Growth
N/A
128.21
52 Week Low
$8.63
$3.50
52 Week High
$10.57
$5.45

Technical Indicators

Market Signals
Indicator
MFA
ABUS
Relative Strength Index (RSI) 34.09 62.69
Support Level N/A $4.12
Resistance Level $9.68 $5.42
Average True Range (ATR) 0.12 0.15
MACD -0.02 0.01
Stochastic Oscillator 12.80 64.44

Price Performance

Historical Comparison
MFA
ABUS

About MFA MFA Financial Inc.

MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets; and Lima One.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: